Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Q4 2019 Syndax Pharmaceuticals Inc Earnings Call Transcript

Mar 03, 2020 / 09:30PM GMT
Release Date Price: $9.27 (-5.41%)
Operator

Good day, everyone, and welcome to the Syndax Fourth Quarter 2019 Earnings Conference Call. Today's call is being recorded.

At this time, I would like to turn the call over to Claudia Styslinger of Argot Partners. Please begin.

Claudia Styslinger
Argot Partners, LLC - IR Associate

Thank you, operator. Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax' fourth quarter and full year 2019 financial and operating results.

I'm Claudia Styslinger with Argot Partners. And with me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Rick Shea, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Michael Metzger, President and Chief Operating Officer; and Dr. Michael Meyers, Chief Medical Officer.

This call is being accompanied by a slide deck that has been posted on the company's website, so I'd ask you to please turn to our forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot